A novel bifunctional maleimido CHX-A″ chelator for conjugation to thiol-containing biomolecules

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 8, 2008, Pages 2679-2683

  Xu, Heng ^a   Baidoo, Kwamena E ^a   Wong, Karen J ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Imaging and or therapies of cancer; Monoclonal antibody; Thiol maleimide chemistry

Indexed keywords

[2 AMINO 3 (4 AMINOPHENYL)PROPYL]CYCLOHEXANE 1,2 DIAMINE N,N,N',N'',N'' PENTAACETIC ACID; ANTIBODY; CHELATING AGENT; INDIUM 111; ISOTHIOCYANIC ACID DERIVATIVE; MALEIMIDE DERIVATIVE; PEPTIDE; RADIOACTIVE MATERIAL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR THERAPY; OVARY CANCER;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; ISOTHIOCYANATES; MALEIMIDES; MOLECULAR STRUCTURE; PENTETIC ACID; SULFHYDRYL COMPOUNDS;

EID: 41849113467     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.03.022     Document Type: Article

References (26)

1. Goldenberg D.M. Cancer Immunol. Immunother. 52 (2003) 281
2. Milenic D.E., and Brechbiel M.W. Cancer Biol. Ther. 3 (2004) 361
3. Wu A.M., and Senter P.D. Nat. Biotechnol. (2005) 1137
4. Milenic D.E., Brady E.D., and Brechbiel M.W. Nat. Rev. Drug Disc. 3 (2004) 488
5. Wahl R.L. J. Nucl. Med. 46 (2005) 128s
6. Borghaei H., and Schilder R.J. Semin. Nucl. Med. 34 (2004) 4
7. Milenic D.E., Garmestani K., Brady E.D., Albert P.S., Ma D., Abdulla A., and Brechbiel M.W. Clin. Cancer Res. 10 (2004) 7834
8. Milenic D.E., Garmestani K., Brady E.D., Albert P., Abdulla A., Flynn J., and Brechbiel M.W. Clin. Cancer Res. 13 (2007) 1926
9. Wu C., Kobayashi H., Sun B., Yoo M., Paik C.H., Gansow O.A., Carrasquillo J.A., Pastan I., and Brechbiel M.W. Bioorg. Med. Chem. 5 (1997) 1925
10. Kobayashi H., Wu C., Yoo T.M., Sun B., Pastan I., Paik C.H., Gansow O.A., Carrasquillo J.A., and Brechbiel M.W. J. Nucl. Med. 39 (1998) 829
11. Nikula T.K., McDevitt M.R., Finn R.D., Wu C., Kozak R.W., Garmestani K., Brechbiel M.W., Curcio M.J., Pippin C.G., Tiffany-Jones L., Geerlings Sr. M.W., Apostolidos C., Molinet R., Geerlings Jr. M.W., Gansow O.A., and Scheinberg D.A. J. Nucl. Med. 40 (1999) 166
12. Milenic D.E., Garmestani K., Chappell L.L., Dadachova E., Yordanov A., Ma D., Schlom J., and Brechbiel M.W. Nucl. Med. Biol. 29 (2002) 431
13. Hermanson G.T. Bioconjugate Techniques (1996), Academic Press, London pp 419-455
14. Arano Y., Uezono T., Akizawa H., Ono M., Wakisaka K., Nakayama M., Sakahara H., Konishi J., and Yokoyama A. J. Med. Chem. 39 (1996) 3451
15. Ali M.S., and Quadri S.M. Bioconjugate Chem. 7 (1996) 576
16. Lewis M.R., and Shively J.E. Bioconjugate Chem. 9 (1998) 72
17. Lattuada L., and Gabellini M. Synth. Commun. 35 (2005) 2409
18. Clifford T., Boswell A.C., Biddlecombe G.B., Lewis J.S., and Brechbiel M.W. J. Med. Chem. 49 (2006) 4297
19. Xu H., Baidoo K., Gunn A.J., Boswell C.A., Milenic D.E., Choyke P.L., and Brechbiel M.W. J. Med. Chem. 50 (2007) 4759
20. +]: 1026.63786. Found 1026.63822.
21. +]: 744.30922. Found 744.30692.
22. Jue R., Lambert J.M., Pierce L.R., and Traut R.R. Biochemistry 17 (1978) 5399
23. Thiolation of and conjugation with trastuzumab: Trastuzumab (∼7.7 mg) was reacted with Traut's reagent at a 1:15 molar ratio for 1 h at rt in 1 mL of PBS containing 5 mM EDTA buffer. Excess Traut's reagent was removed by passage of the reaction solution through a PD-10 column eluted with PBS containing 5 mM EDTA buffer. Just prior to protein conjugation, 5 was dissolved in the same buffer and then added drop wise to the mAb solution to achieve a molar reaction ratio of 10:1 (5:trastuzumab) and gently vortexed. The solution was then gently agitated in the dark at 25 °C for 1 h. Excess free unreacted SH groups were capped by the addition of iodoacetamide solution (2.0 mM). Finally, the reaction mixture was dialyzed into PBS buffer at 4 °C with 4 buffer changes (4× 1 L) over 48 h to afford immunoconjugate 2. Protein concentration and the number of the CHX-A″ chelate per protein were determined by Lowry assay and Arsenazo(III) assay, respectively. The purity of immunoconjugate 2 was evaluated by both SE-HPLC and SDS-PAGE (data not shown), and was found to be comparable to native trastuzumab.
24. Pippin C.G., Parker T.A., McMurry T.J., and Brechbiel M.W. Bioconjugate Chem. 3 (1992) 342
25. 111In labeled product was purified on a PD-10 column using PBS as the eluent. The radiolabeling efficiency was 95.2%.
26. 6/50 μL) in 50 μL of PBS/BSA. The cells were washed with 3 mL of 1% BSA in PBS following an 18 h incubation at room temperature, pelleted at 1000g for 5 min and the supernatant decanted. The radioactivity was measured in a γ-counter (WizardOne, Perkin-Elmer, Shelton, CT) and the percent bound calculated for each dilution. The value presented is the average percent bound.